HC Wainwright Boosts Aravive (NASDAQ:ARAV) Price Target to $12.00

Aravive (NASDAQ:ARAV – Get Rating) had its target price hoisted by HC Wainwright from $7.00 to $12.00 in a report issued on Wednesday morning, The Fly reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Aravive’s FY2027 earnings at $0.78 EPS.

Separately, EF Hutton Acquisition Co. I reaffirmed a buy rating and set a $10.00 price target on shares of Aravive in a report on Tuesday, February 14th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Aravive presently has a consensus rating of Buy and a consensus price target of $9.20.

Aravive Price Performance

ARAV stock opened at $1.96 on Wednesday. The business has a fifty day moving average price of $1.84 and a 200 day moving average price of $1.41. Aravive has a fifty-two week low of $0.58 and a fifty-two week high of $2.23. The stock has a market capitalization of $117.27 million, a price-to-earnings ratio of -0.89 and a beta of 2.35.

Institutional Investors Weigh In On Aravive

Several hedge funds and other institutional investors have recently made changes to their positions in ARAV. Renaissance Technologies LLC boosted its position in shares of Aravive by 35.0% in the 2nd quarter. Renaissance Technologies LLC now owns 374,945 shares of the company’s stock worth $370,000 after purchasing an additional 97,116 shares during the last quarter. Millennium Management LLC boosted its position in shares of Aravive by 58.9% in the 2nd quarter. Millennium Management LLC now owns 96,838 shares of the company’s stock worth $96,000 after purchasing an additional 35,900 shares during the last quarter. Citigroup Inc. bought a new position in shares of Aravive in the 4th quarter worth $29,000. Artal Group S.A. boosted its position in shares of Aravive by 248.7% in the 4th quarter. Artal Group S.A. now owns 4,572,515 shares of the company’s stock worth $6,036,000 after purchasing an additional 3,261,224 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Aravive by 4.6% in the 4th quarter. Geode Capital Management LLC now owns 142,787 shares of the company’s stock worth $188,000 after purchasing an additional 6,238 shares during the last quarter. 16.85% of the stock is owned by institutional investors and hedge funds.

About Aravive

(Get Rating)

Aravive, Inc operates as a clinical stage biotechnology company. The firm engages in the development of new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments and immune suppression.